Lorlatinib (lorlatinib) will be included in medical insurance prices in 2024

Lorlatinib (Lolatinib) is a targeted lung cancer treatment drug, and its inclusion in domestic medical insurance policies is good news for lung cancer patients. Coverage by medical insurance means that patients can alleviate the financial burden of purchasing drugs to a certain extent, because part of the cost of treatment will be borne by the government or local government. Nonetheless, the high price of lorlatinib (lorlatinib) remains an issue that needs attention and improvement.

The price of lorlatinib in the domestic market is about 10,000 to 20,000 yuan, which may be a quite high amount for most patients. However, with its inclusion in Medicare, patients can expect some degree of cost relief. Specific medical insurance reimbursement prices may vary by region, because medical insurance policies and reimbursement standards may differ in different regions. Therefore, patients are advised to consult with local hospital pharmacies before purchasing to obtain accurate medical insurance reimbursement price information.

Althoughlorlatinib (lorlatinib) has a higher domestic price, there are also certain price differences in foreign markets. Türkiye’s original medicines are relatively cheap, priced at more than 7,000 yuan, while Hong Kong’s original medicines cost about 30,000 yuan. In addition, generic drugs produced in some countries are also available on the market, with prices generally ranging from more than one thousand yuan to several thousand yuan. Although the ingredients of original drugs and generic drugs are basically the same, patients need to make sure to choose regular channels when purchasing to ensure the quality and safety of the drugs.

Lorlatinib (lorlatinib)Price included in medical insuranceAlthough the price may still pose a certain financial burden to patients, it has been significantly improved compared to not included in medical insurance. With the support of medical insurance, some patients can obtain a certain degree of cost reduction, making it easier to obtain necessary treatment. For some patients with more difficult economic conditions, this means that they have more treatment options and hope, and can better cope with the challenges of the disease.

However, although inclusion in medical insurance is a positive move, the government, medical institutions and pharmaceutical companies still need to work together to further improve relevant policies, reduce drug prices, and ensure that patients can obtain fair and reasonable medical protection. This requires continuous optimization and adjustment of policies to meet the diverse needs of patients and provide patients with better medical security and services.